Pediatric medulloblastoma in the molecular era: what are the surgical implications?

go back to reference Ellison, D. W., et al. (2011). Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica, 121(3), 381–396.CrossRefPubMedPubMedCentral Ellison, D. W., et al. (2011). Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica, 121(3), 381–396.CrossRefPubMedPubMedCentral

go back to reference Bailey, P., Cushings H. (1925). Medulloblastoma cerebelli:a common type of midcerebellar glioma of childhood. Archives of Neurology and Psychiatry, 14, 192–224.CrossRef Bailey, P., Cushings H. (1925). Medulloblastoma cerebelli:a common type of midcerebellar glioma of childhood. Archives of Neurology and Psychiatry, 14, 192–224.CrossRef

go back to reference Polkinghorn, W. R., & Tarbell, N. J. (2007). Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nature Clinical Practice. Oncology, 4(5), 295–304.CrossRefPubMed Polkinghorn, W. R., & Tarbell, N. J. (2007). Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nature Clinical Practice. Oncology, 4(5), 295–304.CrossRefPubMed

go back to reference Ellison, D. (2002). Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathology and Applied Neurobiology, 28(4), 257–282.CrossRefPubMed Ellison, D. (2002). Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathology and Applied Neurobiology, 28(4), 257–282.CrossRefPubMed

go back to reference Packer, R. J. (2007). Craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. Current Neurology and Neuroscience Reports, 7(2), 130–132. Packer, R. J. (2007). Craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. Current Neurology and Neuroscience Reports, 7(2), 130–132.

go back to reference Packer, R. J., Sutton, L. N., Atkins, T. E., Radcliffe, J., Bunin, G. R., D’Angio, G., Siegel, K. R., & Schut, L. (1989). A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. Journal of Neurosurgery, 70(5), 707–713.CrossRefPubMed Packer, R. J., Sutton, L. N., Atkins, T. E., Radcliffe, J., Bunin, G. R., D’Angio, G., Siegel, K. R., & Schut, L. (1989). A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. Journal of Neurosurgery, 70(5), 707–713.CrossRefPubMed

go back to reference Bull, K. S., et al. (2014). Child-related characteristics predicting subsequent health-related quality of life in 8- to 14-year-old children with and without cerebellar tumors: a prospective longitudinal study. Neurooncol Pract, 1(3), 114–122.PubMedPubMedCentral Bull, K. S., et al. (2014). Child-related characteristics predicting subsequent health-related quality of life in 8- to 14-year-old children with and without cerebellar tumors: a prospective longitudinal study. Neurooncol Pract, 1(3), 114–122.PubMedPubMedCentral

go back to reference Ellison, D. W. (2010). Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathologica, 120(3), 305–316.CrossRefPubMed Ellison, D. W. (2010). Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathologica, 120(3), 305–316.CrossRefPubMed

go back to reference Ris, M. D., Packer, R., Goldwein, J., Jones-Wallace, D., & Boyett, J. M. (2001). Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. Journal of Clinical Oncology, 19(15), 3470–3476.CrossRefPubMed Ris, M. D., Packer, R., Goldwein, J., Jones-Wallace, D., & Boyett, J. M. (2001). Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. Journal of Clinical Oncology, 19(15), 3470–3476.CrossRefPubMed

go back to reference Palmer, S. L., et al. (2003). Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology, 17(4), 548–555.CrossRefPubMed Palmer, S. L., et al. (2003). Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology, 17(4), 548–555.CrossRefPubMed

go back to reference Palmer, S. L., et al. (2001). Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. Journal of Clinical Oncology, 19(8), 2302–2308. Palmer, S. L., et al. (2001). Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. Journal of Clinical Oncology, 19(8), 2302–2308.

go back to reference Mulhern, R. K., Merchant, T. E., Gajjar, A., Reddick, W. E., & Kun, L. E. (2004). Late neurocognitive sequelae in survivors of brain tumours in childhood. The Lancet Oncology, 5(7), 399–408.CrossRefPubMed Mulhern, R. K., Merchant, T. E., Gajjar, A., Reddick, W. E., & Kun, L. E. (2004). Late neurocognitive sequelae in survivors of brain tumours in childhood. The Lancet Oncology, 5(7), 399–408.CrossRefPubMed

go back to reference Yoo, H. J., Kim, H., Park, H. J., Kim, D. S., Ra, Y. S., & Shin, H. Y. (2016). Neurocognitive function and health-related quality of life in pediatric Korean survivors of medulloblastoma. Journal of Korean Medical Science, 31(11), 1726–1734.CrossRefPubMedPubMedCentral Yoo, H. J., Kim, H., Park, H. J., Kim, D. S., Ra, Y. S., & Shin, H. Y. (2016). Neurocognitive function and health-related quality of life in pediatric Korean survivors of medulloblastoma. Journal of Korean Medical Science, 31(11), 1726–1734.CrossRefPubMedPubMedCentral

go back to reference Golub, T. R., et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286(5439), 531–537.CrossRefPubMed Golub, T. R., et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286(5439), 531–537.CrossRefPubMed

go back to reference Pomeroy, S. L., et al. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415(6870), 436–442.CrossRefPubMed Pomeroy, S. L., et al. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415(6870), 436–442.CrossRefPubMed

go back to reference Thompson, M. C., Fuller, C., Hogg, T. L., Dalton, J., Finkelstein, D., Lau, C. C., Chintagumpala, M., Adesina, A., Ashley, D. M., Kellie, S. J., Taylor, M. D., Curran, T., Gajjar, A., & Gilbertson, R. J. (2006). Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. Journal of Clinical Oncology, 24(12), 1924–1931.CrossRefPubMed Thompson, M. C., Fuller, C., Hogg, T. L., Dalton, J., Finkelstein, D., Lau, C. C., Chintagumpala, M., Adesina, A., Ashley, D. M., Kellie, S. J., Taylor, M. D., Curran, T., Gajjar, A., & Gilbertson, R. J. (2006). Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. Journal of Clinical Oncology, 24(12), 1924–1931.CrossRefPubMed

go back to reference Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., Troost, D., Meeteren, N. S., Caron, H. N., Cloos, J., Mrsić, A., Ylstra, B., Grajkowska, W., Hartmann, W., Pietsch, T., Ellison, D., Clifford, S. C., & Versteeg, R. (2008). Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One, 3(8), e3088.CrossRefPubMedPubMedCentral Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., Troost, D., Meeteren, N. S., Caron, H. N., Cloos, J., Mrsić, A., Ylstra, B., Grajkowska, W., Hartmann, W., Pietsch, T., Ellison, D., Clifford, S. C., & Versteeg, R. (2008). Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One, 3(8), e3088.CrossRefPubMedPubMedCentral

go back to reference Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., Rutka, J. T., Pfister, S., & Taylor, M. D. (2011). Medulloblastoma comprises four distinct molecular variants. Journal of Clinical Oncology, 29(11), 1408–1414.CrossRefPubMed Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., Rutka, J. T., Pfister, S., & Taylor, M. D. (2011). Medulloblastoma comprises four distinct molecular variants. Journal of Clinical Oncology, 29(11), 1408–1414.CrossRefPubMed

go back to reference Cho, Y. J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C. G., Lau, C. C., Olson, J. M., Gilbertson, R. J., Gajjar, A., Delattre, O., Kool, M., Ligon, K., Meyerson, M., Mesirov, J. P., & Pomeroy, S. L. (2011). Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Journal of Clinical Oncology, 29(11), 1424–1430.CrossRefPubMed Cho, Y. J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C. G., Lau, C. C., Olson, J. M., Gilbertson, R. J., Gajjar, A., Delattre, O., Kool, M., Ligon, K., Meyerson, M., Mesirov, J. P., & Pomeroy, S. L. (2011). Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Journal of Clinical Oncology, 29(11), 1424–1430.CrossRefPubMed

go back to reference Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., Ellison, D. W., Lichter, P., Gilbertson, R. J., Pomeroy, S. L., Kool, M., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 123(4), 465–472.CrossRefPubMed Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., Ellison, D. W., Lichter, P., Gilbertson, R. J., Pomeroy, S. L., Kool, M., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 123(4), 465–472.CrossRefPubMed

go back to reference Kool, M., Korshunov, A., Remke, M., Jones, D. T., Schlanstein, M., Northcott, P. A., Cho, Y. J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., Clifford, S. C., Pietsch, T., von Bueren, A., Rutkowski, S., McCabe, M., Collins, V. P., Bäcklund, M. L., Haberler, C., Bourdeaut, F., Delattre, O., Doz, F., Ellison, D. W., Gilbertson, R. J., Pomeroy, S. L., Taylor, M. D., Lichter, P., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathologica, 123(4), 473–484.CrossRefPubMedPubMedCentral Kool, M., Korshunov, A., Remke, M., Jones, D. T., Schlanstein, M., Northcott, P. A., Cho, Y. J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., Clifford, S. C., Pietsch, T., von Bueren, A., Rutkowski, S., McCabe, M., Collins, V. P., Bäcklund, M. L., Haberler, C., Bourdeaut, F., Delattre, O., Doz, F., Ellison, D. W., Gilbertson, R. J., Pomeroy, S. L., Taylor, M. D., Lichter, P., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathologica, 123(4), 473–484.CrossRefPubMedPubMedCentral

go back to reference Clifford, S. C., Lusher, M. E., Lindsey, J. C., Langdon, J. A., Gilbertson, R. J., Straughton, D., & Ellison, D. W. (2006). Wnt/wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle, 5(22), 2666–2670.CrossRefPubMed Clifford, S. C., Lusher, M. E., Lindsey, J. C., Langdon, J. A., Gilbertson, R. J., Straughton, D., & Ellison, D. W. (2006). Wnt/wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle, 5(22), 2666–2670.CrossRefPubMed

go back to reference Ellison, D. W., et al. (2005). Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology, 23(31), 7951–7957.CrossRefPubMed Ellison, D. W., et al. (2005). Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology, 23(31), 7951–7957.CrossRefPubMed

go back to reference Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica, 131(6), 803–820.CrossRefPubMed Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica, 131(6), 803–820.CrossRefPubMed

go back to reference Ramaswamy, V., Remke M, Bouffet E., Bailey S., Clifford SC., et al. (2016). Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 131(6), 821–31. Ramaswamy, V., Remke M, Bouffet E., Bailey S., Clifford SC., et al. (2016). Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 131(6), 821–31.

go back to reference Johnston, D. L., et al. (2018). Survival following tumor recurrence in children with medulloblastoma. Journal of Pediatric Hematology/Oncology. Johnston, D. L., et al. (2018). Survival following tumor recurrence in children with medulloblastoma. Journal of Pediatric Hematology/Oncology.

go back to reference Johnston, D. L., Keene, D., Kostova, M., Lafay-Cousin, L., Fryer, C., Scheinemann, K., Carret, A. S., Fleming, A., Percy, V., Afzal, S., Wilson, B., Bowes, L., Zelcer, S., Mpofu, C., Silva, M., Larouche, V., Brossard, J., Strother, D., & Bouffet, E. (2015). Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive. Journal of Neuro-Oncology, 124(2), 247–253.CrossRefPubMed Johnston, D. L., Keene, D., Kostova, M., Lafay-Cousin, L., Fryer, C., Scheinemann, K., Carret, A. S., Fleming, A., Percy, V., Afzal, S., Wilson, B., Bowes, L., Zelcer, S., Mpofu, C., Silva, M., Larouche, V., Brossard, J., Strother, D., & Bouffet, E. (2015). Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive. Journal of Neuro-Oncology, 124(2), 247–253.CrossRefPubMed

go back to reference Koschmann, C., et al. (2016). Survival after relapse of medulloblastoma. Journal of Pediatric Hematology/Oncology, 38(4), 269–273.CrossRefPubMed Koschmann, C., et al. (2016). Survival after relapse of medulloblastoma. Journal of Pediatric Hematology/Oncology, 38(4), 269–273.CrossRefPubMed

go back to reference Sabel, M., Fleischhack, G., Tippelt, S., Gustafsson, G., Doz, F., Kortmann, R., Massimino, M., Navajas, A., von Hoff, K., Rutkowski, S., Warmuth-Metz, M., Clifford, S. C., Pietsch, T., Pizer, B., Lannering, B., & SIOP-E Brain Tumour Group. (2016). Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. Journal of Neuro-Oncology, 129(3), 515–524.CrossRefPubMedPubMedCentral Sabel, M., Fleischhack, G., Tippelt, S., Gustafsson, G., Doz, F., Kortmann, R., Massimino, M., Navajas, A., von Hoff, K., Rutkowski, S., Warmuth-Metz, M., Clifford, S. C., Pietsch, T., Pizer, B., Lannering, B., & SIOP-E Brain Tumour Group. (2016). Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. Journal of Neuro-Oncology, 129(3), 515–524.CrossRefPubMedPubMedCentral

go back to reference Bowers, D. C., Gargan, L., Weprin, B. E., Mulne, A. F., Elterman, R. D., Munoz, L., Giller, C. A., & Winick, N. J. (2007). Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma. Journal of Neurosurgery, 107(1 Suppl), 5–10.PubMed Bowers, D. C., Gargan, L., Weprin, B. E., Mulne, A. F., Elterman, R. D., Munoz, L., Giller, C. A., & Winick, N. J. (2007). Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma. Journal of Neurosurgery, 107(1 Suppl), 5–10.PubMed

go back to reference Perreault, S., Lober, R. M., Carret, A. S., Zhang, G., Hershon, L., Décarie, J. C., Yeom, K., Vogel, H., Fisher, P. G., & Partap, S. (2013). Relapse patterns in pediatric embryonal central nervous system tumors. Journal of Neuro-Oncology, 115(2), 209–215.CrossRefPubMed Perreault, S., Lober, R. M., Carret, A. S., Zhang, G., Hershon, L., Décarie, J. C., Yeom, K., Vogel, H., Fisher, P. G., & Partap, S. (2013). Relapse patterns in pediatric embryonal central nervous system tumors. Journal of Neuro-Oncology, 115(2), 209–215.CrossRefPubMed

go back to reference Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., Agnihotri, S., Thompson, Y. Y., Kuzan-Fischer, C. M., Farooq, H., Isaev, K., Daniels, C., Cho, B. K., Kim, S. K., Wang, K. C., Lee, J. Y., Grajkowska, W. A., Perek-Polnik, M., Vasiljevic, A., Faure-Conter, C., Jouvet, A., Giannini, C., Nageswara Rao, A. A., Li, K. K. W., Ng, H. K., Eberhart, C. G., Pollack, I. F., Hamilton, R. L., Gillespie, G. Y., Olson, J. M., Leary, S., Weiss, W. A., Lach, B., Chambless, L. B., Thompson, R. C., Cooper, M. K., Vibhakar, R., Hauser, P., van Veelen, M., Kros, J. M., French, P. J., Ra, Y. S., Kumabe, T., López-Aguilar, E., Zitterbart, K., Sterba, J., Finocchiaro, G., Massimino, M., van Meir, E., Osuka, S., Shofuda, T., Klekner, A., Zollo, M., Leonard, J. R., Rubin, J. B., Jabado, N., Albrecht, S., Mora, J., van Meter, T., Jung, S., Moore, A. S., Hallahan, A. R., Chan, J. A., Tirapelli, D. P. C., Carlotti, C. G., Fouladi, M., Pimentel, J., Faria, C. C., Saad, A. G., Massimi, L., Liau, L. M., Wheeler, H., Nakamura, H., Elbabaa, S. K., Perezpeña-Diazconti, M., Chico Ponce de León, F., Robinson, S., Zapotocky, M., Lassaletta, A., Huang, A., Hawkins, C. E., Tabori, U., Bouffet, E., Bartels, U., Dirks, P. B., Rutka, J. T., Bader, G. D., Reimand, J., Goldenberg, A., Ramaswamy, V., & Taylor, M. D. (2017). Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell, 31(6), 737–754 e6.CrossRefPubMedPubMedCentral Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., Agnihotri, S., Thompson, Y. Y., Kuzan-Fischer, C. M., Farooq, H., Isaev, K., Daniels, C., Cho, B. K., Kim, S. K., Wang, K. C., Lee, J. Y., Grajkowska, W. A., Perek-Polnik, M., Vasiljevic, A., Faure-Conter, C., Jouvet, A., Giannini, C., Nageswara Rao, A. A., Li, K. K. W., Ng, H. K., Eberhart, C. G., Pollack, I. F., Hamilton, R. L., Gillespie, G. Y., Olson, J. M., Leary, S., Weiss, W. A., Lach, B., Chambless, L. B., Thompson, R. C., Cooper, M. K., Vibhakar, R., Hauser, P., van Veelen, M., Kros, J. M., French, P. J., Ra, Y. S., Kumabe, T., López-Aguilar, E., Zitterbart, K., Sterba, J., Finocchiaro, G., Massimino, M., van Meir, E., Osuka, S., Shofuda, T., Klekner, A., Zollo, M., Leonard, J. R., Rubin, J. B., Jabado, N., Albrecht, S., Mora, J., van Meter, T., Jung, S., Moore, A. S., Hallahan, A. R., Chan, J. A., Tirapelli, D. P. C., Carlotti, C. G., Fouladi, M., Pimentel, J., Faria, C. C., Saad, A. G., Massimi, L., Liau, L. M., Wheeler, H., Nakamura, H., Elbabaa, S. K., Perezpeña-Diazconti, M., Chico Ponce de León, F., Robinson, S., Zapotocky, M., Lassaletta, A., Huang, A., Hawkins, C. E., Tabori, U., Bouffet, E., Bartels, U., Dirks, P. B., Rutka, J. T., Bader, G. D., Reimand, J., Goldenberg, A., Ramaswamy, V., & Taylor, M. D. (2017). Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell, 31(6), 737–754 e6.CrossRefPubMedPubMedCentral

go back to reference Ramaswamy, V., Remke, M., Bouffet, E., Faria, C. C., Perreault, S., Cho, Y. J., Shih, D. J., Luu, B., Dubuc, A. M., Northcott, P. A., Schüller, U., Gururangan, S., McLendon, R., Bigner, D., Fouladi, M., Ligon, K. L., Pomeroy, S. L., Dunn, S., Triscott, J., Jabado, N., Fontebasso, A., Jones, D. T., Kool, M., Karajannis, M. A., Gardner, S. L., Zagzag, D., Nunes, S., Pimentel, J., Mora, J., Lipp, E., Walter, A. W., Ryzhova, M., Zheludkova, O., Kumirova, E., Alshami, J., Croul, S. E., Rutka, J. T., Hawkins, C., Tabori, U., Codispoti, K. E., Packer, R. J., Pfister, S. M., Korshunov, A., & Taylor, M. D. (2013). Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. The Lancet Oncology, 14(12), 1200–1207.CrossRefPubMedPubMedCentral Ramaswamy, V., Remke, M., Bouffet, E., Faria, C. C., Perreault, S., Cho, Y. J., Shih, D. J., Luu, B., Dubuc, A. M., Northcott, P. A., Schüller, U., Gururangan, S., McLendon, R., Bigner, D., Fouladi, M., Ligon, K. L., Pomeroy, S. L., Dunn, S., Triscott, J., Jabado, N., Fontebasso, A., Jones, D. T., Kool, M., Karajannis, M. A., Gardner, S. L., Zagzag, D., Nunes, S., Pimentel, J., Mora, J., Lipp, E., Walter, A. W., Ryzhova, M., Zheludkova, O., Kumirova, E., Alshami, J., Croul, S. E., Rutka, J. T., Hawkins, C., Tabori, U., Codispoti, K. E., Packer, R. J., Pfister, S. M., Korshunov, A., & Taylor, M. D. (2013). Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. The Lancet Oncology, 14(12), 1200–1207.CrossRefPubMedPubMedCentral

go back to reference Packer, R. J., Zhou, T., Holmes, E., Vezina, G., & Gajjar, A. (2013). Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961. Neuro-Oncology, 15(1), 97–103.CrossRefPubMed Packer, R. J., Zhou, T., Holmes, E., Vezina, G., & Gajjar, A. (2013). Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961. Neuro-Oncology, 15(1), 97–103.CrossRefPubMed

go back to reference Kameda-Smith, M. M., Wang, A., Abdulhadi, N., Voth, R., Sergeant, A., Maharaj, A., Bakhshinyan, D., Adile, A. A., Pai, A. M., Ajani, O., Yarascavitch, B., Alyman, M. C., Duckworth, J., Samaan, M. C., Farrokhyar, F., Singh, S. K., Fleming, A., & Pediatric Brain Tumour Study Group. (2019). Salvage therapy for childhood medulloblastoma: a single center experience. The Canadian Journal of Neurological Sciences, 46(4), 403–414.CrossRefPubMed Kameda-Smith, M. M., Wang, A., Abdulhadi, N., Voth, R., Sergeant, A., Maharaj, A., Bakhshinyan, D., Adile, A. A., Pai, A. M., Ajani, O., Yarascavitch, B., Alyman, M. C., Duckworth, J., Samaan, M. C., Farrokhyar, F., Singh, S. K., Fleming, A., & Pediatric Brain Tumour Study Group. (2019). Salvage therapy for childhood medulloblastoma: a single center experience. The Canadian Journal of Neurological Sciences, 46(4), 403–414.CrossRefPubMed

go back to reference Robinson, G. W., et al. (2018). Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. The Lancet Oncology, 19(6), 768–784.CrossRefPubMedPubMedCentral Robinson, G. W., et al. (2018). Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. The Lancet Oncology, 19(6), 768–784.CrossRefPubMedPubMedCentral

go back to reference Lafay-Cousin, L., Bouffet, E., Onar-Thomas, A., Billups, C. A., Hawkins, C., Eberhart, C., Horbinski, C., Robinson, G. W., Strother, D. R., Heier, L., Souweidane, M. M., Fouladi, M., Gajjar, A., & Children Oncology Group. (2017). ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age-a report of the Children Oncology Group. Journal of Clinical Oncology,35(15_suppl), 10505–10505.CrossRef Lafay-Cousin, L., Bouffet, E., Onar-Thomas, A., Billups, C. A., Hawkins, C., Eberhart, C., Horbinski, C., Robinson, G. W., Strother, D. R., Heier, L., Souweidane, M. M., Fouladi, M., Gajjar, A., & Children Oncology Group. (2017). ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age-a report of the Children Oncology Group. Journal of Clinical Oncology,35(15_suppl), 10505–10505.CrossRef

go back to reference ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier: NCT03434262, SJDWAN: St. Jude Children's Research Hospital Phase 1 study evaluating molecularly-driven doublet therapies for children and young adults with recurrent brain tumours. Available from: https://clinicaltrials.gov/ct2/show/NCT03434262?term;SJDAWN&draw;2&rank;1. Accessed 31 Oct 2019. ClinicalTrials.​gov. Bethesda (MD): National Library of Medicine (US). Identifier: NCT03434262, SJDWAN: St. Jude Children's Research Hospital Phase 1 study evaluating molecularly-driven doublet therapies for children and young adults with recurrent brain tumours. Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT03434262?​term;SJDAWN&​draw;2&​rank;1. Accessed 31 Oct 2019.

go back to reference Perreault, S., Ramaswamy, V., Achrol, A. S., Chao, K., Liu, T. T., Shih, D., Remke, M., Schubert, S., Bouffet, E., Fisher, P. G., Partap, S., Vogel, H., Taylor, M. D., Cho, Y. J., & Yeom, K. W. (2014). MRI surrogates for molecular subgroups of medulloblastoma. AJNR. American Journal of Neuroradiology, 35(7), 1263–1269.CrossRefPubMedPubMedCentral Perreault, S., Ramaswamy, V., Achrol, A. S., Chao, K., Liu, T. T., Shih, D., Remke, M., Schubert, S., Bouffet, E., Fisher, P. G., Partap, S., Vogel, H., Taylor, M. D., Cho, Y. J., & Yeom, K. W. (2014). MRI surrogates for molecular subgroups of medulloblastoma. AJNR. American Journal of Neuroradiology, 35(7), 1263–1269.CrossRefPubMedPubMedCentral

go back to reference Mata-Mbemba, D., Zapotocky, M., Laughlin, S., Taylor, M. D., Ramaswamy, V., & Raybaud, C. (2018). MRI characteristics of primary tumors and metastatic lesions in molecular subgroups of pediatric medulloblastoma: a single-center study. AJNR. American Journal of Neuroradiology, 39(5), 949–955.CrossRefPubMedPubMedCentral Mata-Mbemba, D., Zapotocky, M., Laughlin, S., Taylor, M. D., Ramaswamy, V., & Raybaud, C. (2018). MRI characteristics of primary tumors and metastatic lesions in molecular subgroups of pediatric medulloblastoma: a single-center study. AJNR. American Journal of Neuroradiology, 39(5), 949–955.CrossRefPubMedPubMedCentral

go back to reference Lastowska, M., et al. (2018). Medulloblastoma with transitional features between group 3 and group 4 is associated with good prognosis. Journal of Neuro-Oncology, 138(2), 231–240.CrossRefPubMedPubMedCentral Lastowska, M., et al. (2018). Medulloblastoma with transitional features between group 3 and group 4 is associated with good prognosis. Journal of Neuro-Oncology, 138(2), 231–240.CrossRefPubMedPubMedCentral

go back to reference Bonner, E. R., et al. (2018). Liquid biopsy for pediatric central nervous system tumors. NPJ Precis Oncol, 2, 29.CrossRefPubMedPubMedCentral Bonner, E. R., et al. (2018). Liquid biopsy for pediatric central nervous system tumors. NPJ Precis Oncol, 2, 29.CrossRefPubMedPubMedCentral

go back to reference Phoenix, T. N., et al. (2016). Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell, 29(4), 508–522.CrossRefPubMedPubMedCentral Phoenix, T. N., et al. (2016). Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell, 29(4), 508–522.CrossRefPubMedPubMedCentral

go back to reference Moxon-Emre, I., Bouffet, E., Taylor, M. D., Laperriere, N., Scantlebury, N., Law, N., Spiegler, B. J., Malkin, D., Janzen, L., & Mabbott, D. (2014). Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. Journal of Clinical Oncology, 32(17), 1760–1768.CrossRefPubMed Moxon-Emre, I., Bouffet, E., Taylor, M. D., Laperriere, N., Scantlebury, N., Law, N., Spiegler, B. J., Malkin, D., Janzen, L., & Mabbott, D. (2014). Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. Journal of Clinical Oncology, 32(17), 1760–1768.CrossRefPubMed

go back to reference ClinicalTrials.gov, A study assessing the feasibility of a surgery and chemotherapy-only in children with Wnt positive medulloblastoma. 2018, ethesda (MD): National Library of Medicine (US). ClinicalTrials.gov, A study assessing the feasibility of a surgery and chemotherapy-only in children with Wnt positive medulloblastoma. 2018, ethesda (MD): National Library of Medicine (US).

go back to reference ClinicalTrials.gov, Reduced craniospinal radiation therapy and chemotherapy in treating younger patients with newly diagnosed WNT-driven medulloblastoma. 2018, National Library of Medicine (US): Bethesda (MD). ClinicalTrials.gov, Reduced craniospinal radiation therapy and chemotherapy in treating younger patients with newly diagnosed WNT-driven medulloblastoma. 2018, National Library of Medicine (US): Bethesda (MD).

go back to reference ClinicalTrials.gov, A clinical and molecular risk-directed therapy for newly diagnosed medulloblastoma. 2013: Bethesda (MD): National Library of Medicine (US). ClinicalTrials.gov, A clinical and molecular risk-directed therapy for newly diagnosed medulloblastoma. 2013: Bethesda (MD): National Library of Medicine (US).

go back to reference ClinicalTrials.gov, International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma. 2014, ethesda (MD): National Library of Medicine (US). ClinicalTrials.gov, International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma. 2014, ethesda (MD): National Library of Medicine (US).

go back to reference Kameda-Smith, M. M., et al. (2013). Time to diagnosis of paediatric posterior fossa tumours: an 11-year west of Scotland experience 2000-2011. British Journal of Neurosurgery, 27(3), 364–369.CrossRefPubMed Kameda-Smith, M. M., et al. (2013). Time to diagnosis of paediatric posterior fossa tumours: an 11-year west of Scotland experience 2000-2011. British Journal of Neurosurgery, 27(3), 364–369.CrossRefPubMed

go back to reference Sergeant, A., et al. (2017). Analysis of surgical and MRI factors associated with cerebellar mutism. Journal of Neuro-Oncology, 133(3), 539–552.CrossRefPubMed Sergeant, A., et al. (2017). Analysis of surgical and MRI factors associated with cerebellar mutism. Journal of Neuro-Oncology, 133(3), 539–552.CrossRefPubMed

go back to reference Gottardo, N. G., Hansford, J. R., McGlade, J., Alvaro, F., Ashley, D. M., Bailey, S., Baker, D. L., Bourdeaut, F., Cho, Y. J., Clay, M., Clifford, S. C., Cohn, R. J., Cole, C. H., Dallas, P. B., Downie, P., Doz, F., Ellison, D. W., Endersby, R., Fisher, P. G., Hassall, T., Heath, J. A., Hii, H. L., Jones, D. T., Junckerstorff, R., Kellie, S., Kool, M., Kotecha, R. S., Lichter, P., Laughton, S. J., Lee, S., McCowage, G., Northcott, P. A., Olson, J. M., Packer, R. J., Pfister, S. M., Pietsch, T., Pizer, B., Pomeroy, S. L., Remke, M., Robinson, G. W., Rutkowski, S., Schoep, T., Shelat, A. A., Stewart, C. F., Sullivan, M., Taylor, M. D., Wainwright, B., Walwyn, T., Weiss, W. A., Williamson, D., & Gajjar, A. (2014). Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathologica, 127(2), 189–201.CrossRefPubMed Gottardo, N. G., Hansford, J. R., McGlade, J., Alvaro, F., Ashley, D. M., Bailey, S., Baker, D. L., Bourdeaut, F., Cho, Y. J., Clay, M., Clifford, S. C., Cohn, R. J., Cole, C. H., Dallas, P. B., Downie, P., Doz, F., Ellison, D. W., Endersby, R., Fisher, P. G., Hassall, T., Heath, J. A., Hii, H. L., Jones, D. T., Junckerstorff, R., Kellie, S., Kool, M., Kotecha, R. S., Lichter, P., Laughton, S. J., Lee, S., McCowage, G., Northcott, P. A., Olson, J. M., Packer, R. J., Pfister, S. M., Pietsch, T., Pizer, B., Pomeroy, S. L., Remke, M., Robinson, G. W., Rutkowski, S., Schoep, T., Shelat, A. A., Stewart, C. F., Sullivan, M., Taylor, M. D., Wainwright, B., Walwyn, T., Weiss, W. A., Williamson, D., & Gajjar, A. (2014). Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathologica, 127(2), 189–201.CrossRefPubMed

go back to reference ClinicalTrials.gov, A dose exploration study with MK-8628 in participants with selected advanced solid tumors (MK-8628-006). 2018, Bethesda (MD): National Library of Medicine (US). ClinicalTrials.gov, A dose exploration study with MK-8628 in participants with selected advanced solid tumors (MK-8628-006). 2018, Bethesda (MD): National Library of Medicine (US).

go back to reference ClinicalTrials.gov, A dose-finding study of MK-8628, a small molecule inhibitor of the bromodomain and extra-terminal (BET) proteins, in adults with selected advanced solid tumors (MK-8628-003). 2018, National Library of Medicine (US). Bethesda (MD). ClinicalTrials.gov, A dose-finding study of MK-8628, a small molecule inhibitor of the bromodomain and extra-terminal (BET) proteins, in adults with selected advanced solid tumors (MK-8628-003). 2018, National Library of Medicine (US). Bethesda (MD).

go back to reference Graff, J. N., Higano, C. S., Hahn, N. M., Taylor, M. H., Zhang, B., Zhou, X., Venkatakrishnan, K., Leonard, E. J., & Sarantopoulos, J. (2016). Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora a kinase inhibitor, with docetaxel in patients with solid tumors. Cancer, 122(16), 2524–2533.CrossRefPubMed Graff, J. N., Higano, C. S., Hahn, N. M., Taylor, M. H., Zhang, B., Zhou, X., Venkatakrishnan, K., Leonard, E. J., & Sarantopoulos, J. (2016). Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora a kinase inhibitor, with docetaxel in patients with solid tumors. Cancer, 122(16), 2524–2533.CrossRefPubMed

go back to reference Schoffski, P., et al. (2011). Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. European Journal of Cancer, 47(15), 2256–2264.CrossRefPubMed Schoffski, P., et al. (2011). Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. European Journal of Cancer, 47(15), 2256–2264.CrossRefPubMed

go back to reference Seymour, J. F., et al. (2014). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal, 4, e238.CrossRefPubMedPubMedCentral Seymour, J. F., et al. (2014). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal, 4, e238.CrossRefPubMedPubMedCentral

go back to reference Bouffet, E. (2019). Management of high-risk medulloblastoma. Neurochirurgie. Bouffet, E. (2019). Management of high-risk medulloblastoma. Neurochirurgie.

go back to reference Thompson, E. M., et al. (2016). Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet Oncology. Thompson, E. M., et al. (2016). Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet Oncology.